1Neuroprotective effects of erythropoietin on neurodegenerative and ischemic brain diseases: the role of erythropoietin receptor1381-1389
4Post electrical or lightning injury syndrome: a proposal for an American Psychiatric Association's Diagnostic and Statistical Manual formulation with implications for treatment1405-1412
5Tp53 gene mediates distinct dopaminergic neuronal damage in different dopaminergic neurotoxicant models1413-1417
6Therapeutic potential of α7 nicotinic receptor agonists to regulate neuroinflammation in neurodegenerative diseases1418-1421
9Relevance and therapeutic potential of CypA targeting to block apoptosis inducing factor-mediated neuronal cell death1428-1429
10Extracellular matrix based biomaterials for central nervous system tissue repair: the benefits and drawbacks1430-1432
11Interleukin 4-induced neuroprotection and regulation of microglia activation as a therapeutic approach in the MPTP model of Parkinson's disease1433-1434
13Can we switch production of toxic Aβ oligomers to neuroprotective Aβ monomers to allow synapse regeneration?1437-1438
14Glyco-sphingo biology: a novel perspective for potential new treatments in Huntington's disease1439-1440
16Constraint-induced movement therapy in treatment of acute and sub-acute stroke: a meta-analysis of 16 randomized controlled trials1443-1450
17Therapeutic efficacy and safety of various botulinum toxin A doses and concentrations in spastic foot after stroke: a randomized controlled trial1451-1457
18Effect of hyperthermia on calbindin-D 28k immunoreactivity in the hippocampal formation following transient global cerebral ischemia in gerbils1458-1464
19Corticoreticular tract lesion in children with developmental delay presenting with gait dysfunction and trunk instability1465-1471
20Extracellular signal-regulated kinase, substance P and neurokinin-1 are involved in the analgesic mechanism of herb-partitioned moxibustion1472-1478
